FRONTIER SCIENCE | PUBLICATIONS

The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy

OVERVIEW

Reported data for the prespecified secondary endpoints of event-free and overall survival, and assess the association between these outcomes and pathological complete response the the Neo-ALTTO trial.

STUDY DETAILS

The Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study is a randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer.

 Title of Publication

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

AUTHORS

De Azambuja, E., Holmes, A.P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R.F., Untch, M., Jackisch, C., Lang, I., Smith, I. and Boyle, F., Xu, B., Barrios, C.H., Perez, E.A., Azim, H.A., Kim, S-B., Kuemmel, S. Huang, C-S., Vuylsteke, P., Hsieh, R-K., Gorbunova, V., Eniu, A., Dreosti, L., Tavartkiladze, N., Gelber, R.D., Eidtmann, H., and Baselga, J.

Publication Reference

The Lancet Oncology | Volume 15 | Issue 10 | Page(s) 1137-1146 | 2014

 

READ FULL PUBLICATION

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

Apr 1, 2023

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more
APHINITY | European Journal of Cancer (EJC)

APHINITY | European Journal of Cancer (EJC)

Mar 18, 2022

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

read more
APHINITY | AACR Cancer Research

APHINITY | AACR Cancer Research

Feb 15, 2022

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.

read more